News

Phase Holographic Imaging launches new website

Today Phase Holographic Imaging (PHI) launches a new website. The new website has been created to comprehensively provide extensive product information, as well as an introduction to the range of cell biology applications supported by the HoloMonitor® system. The new site provides improved navigation and has been designed using modern technology ensuring compliance with various… Read More »

University of California, San Francisco and Phase Holographic Imaging establish Center of Excellence

University of California, San Francisco (UCSF) and Phase Holographic Imaging (PHI) have agreed to expand their on-going collaboration and establish a regional Holographic Imaging Cytometry Center of Excellence, located at the UCSF Helen Diller Family Comprehensive Cancer Center.

Novel HoloMonitor method identifies tumor creating cancer cells

Using HoloMonitor®, researchers at Harvard Medical School and Boston Children’s Hospital have developed a novel non-invasive method for distinguishing between active and dormant cancer cells.

PHI Launches Wound Healing Assay

HoloMonitor® Wound Healing Assay: The assay meets the unmet market demand of both quantifying cell movement automatically and in great detail. Wound healing assays are one of the most used laboratory methods to study cell movement. Conventional wound healing assays are either manual or just measure the collective movement of a cell population.

Leading Australian Research Institute Purchases HoloMonitor

A first HoloMonitor was recently deployed at QIMR Berghofer Medical Research Institute in Brisbane Australia. With the purchase, the institute upgrades its quantitative time-lapse cytometry capacity to also include instrumentation for measuring the behavior of individual cells in a cell population, without requiring the cells to be labeled with toxic chemicals or through genetic manipulation.

PHI and Malmö University receives 2.3 million SEK to detect blood-borne cancer cells

PHI and a group of experts associated with Malmö University was recently awarded a 2.3 million kronor grant by the Knowledge Foundation (KK-stiftelsen, Sweden). In close collaboration with GlycoImaging, the funded project aim to develop new methods for detecting blood-borne metastatic cancer cells. There are today no simple methods to detect cancer – with a… Read More »

Novel HoloMonitor based research to be presented at cancer research annual meeting

The research results by three research groups at Northeastern University and Lund University will be presented at the American Association for Cancer Research Annual Meeting in April. Using HoloMonitor® technology from PHI the scientists have been able to follow and measure important dynamics of cancer cells in ways not possible with conventional methods, which has led to the… Read More »

Japan´s foremost medical institute purchases multiple HoloMonitor instruments

Japan’s foremost medical research institute, The Institute of Medical Science at University of Tokyo, recently purchased two HoloMonitor M4.5 instruments for a total list price of €75 000, excluding discount. Together with RIKEN and Kyoto University, the institute spearheads Japan’s national effort to become the undisputed leader of regenerative medicine in the world. Stem cells transform… Read More »

EU grants 2.1 million euro to Phase Holographic Imaging and Malmö University with partners for joint cancer research

The European Commission has appointed Phase Holographic Imaging,Bundesanstalt für Material-forschung und Prüfung (Germany’s federal technology research institute), Malmö, Umeå, Copenhagen and Turku University to develop improved methods for clinically diagnosing cancer. The €2.1 million grant finances a three-year research project which is coordinated by Malmö University and commercialized by Phase Holographic Imaging (PHI). Current methods for… Read More »

American association of cancer research highlights article published by PHI collaborators

Oct 5, 2016 AMERICAN ASSOCIATION OF CANCER RESEARCH HIGHLIGHTS ARTICLE PUBLISHED BY PHI COLLABORATORS In the October issue of Molecular Cancer Therapeutics the American Association of Cancer Research (AACR) highlights the novel nano­medicine against ovarian cancer developed by scientists from the Center for Pharma­ceutical Bio­tech­nology and Nano­medicine at North­eastern University. PHI maintains the Holographic Imaging Cytometry Program of… Read More »

Design by Clavis Communications